VGX Pharmaceuticals announces successful completion of the first human study to assess the tolerability of CELLECTRA™ electroporator

Blue Bell, PA – December 27, 2007 –

VGX Pharmaceuticals announced today the successful completion of its first study to assess the tolerability of VGX's patented CELLECTRA™ electroporation device in humans. Ten healthy adult volunteers were treated with the CELLECTRA™ device and were asked to report the level of discomfort they experienced immediately after electroporation and at various times thereafter. The procedure was generally well tolerated. On average, the patients reported a moderate level of discomfort during the procedure. However, the discomfort was short-lived, with comfort levels approaching baseline levels within 30 minutes following the procedure. Other complaints were mild and did not require any treatment.

Numerous preclinical efficacy studies have shown that delivery of VGX's DNA products with the CELLECTRA™ device resulted in therapeutic and protective immune responses that are unachievable by other treatment or vaccine methods.

"The completion of this Human Tolerability Study is a major milestone for VGX Pharmaceuticals," stated Dr. J. Joseph Kim, President and Chief Executive Officer. "This is just the first step in our aggressive strategy to develop a potent and prolific DNA-based drug and vaccine development platform."

Over the years, VGX Pharmaceuticals has established itself as a leading developer and manufacturer of DNA plasmid-based vaccines and therapies. The Company has built extensive, vertically-integrated capabilities including SynCon™ DNA-based product candidates, the CELLECTRA™ delivery device, and efficient cGMP manufacturing facilities for its own product supplies and for contract manufacturing.

PENNVAX™-B vaccine, the first of VGX Pharmaceuticals' SynCon™ DNA vaccine candidates, is already in Phase I clinical trials as a preventative vaccine for HIV infection. VGX Pharmaceuticals plans to file three additional INDs for its SynCon™ DNA vaccine candidates during the first two quarters of 2008: VGX-3100, a therapeutic vaccine for the treatment for cervical cancer; VGX-3200, a therapeutic based on human growth hormone releasing hormone (GHRH) for cancer-related cachexia (wasting or heavy weight loss); and VGX-3400, a pandemic avian flu vaccine. All of these vaccines are delivered by the CELLECTRA™ device.

VGX Pharmaceuticals operates a 500-liter scale cGMP DNA plasmid manufacturing facility in The Woodlands, Texas. In addition, the Company has initiated a project to build and operate a 3000-liter cGMP manufacturing facility in Korea with its affiliate, VGX International.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:
Kevin W. Rassas
Senior Vice President

Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com